Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Florida Jan 28, 2021
Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021 Jan 20, 2021
Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and Completion of $5 Million Bridge Loan Jan 20, 2021
Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor Nov 25, 2020
Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing Nov 19, 2020
Interpace Biosciences Announces Results of Seminal Clinical Validation Study for Thyroid Assays Oct 26, 2020
Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing Aug 20, 2020
